Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?-Reference-Cited by-同舟云学术

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

Published:2000-05 Issue:9218 Volume:355 Page:1869-1874
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Aebi Stefan,Gelber S,Castiglione-Gertsch M,Gelber RD,Collins J,Thürlimann B,Rudenstam CM,Lindtner J,Crivellari D,Cortes-Funes H,Simoncini E,Werner ID,Coates AS,Goldhirsch A

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Breast carcinomas occurring in young women (<35 years) are different;Walker;Br J Cancer,1996

2. Early-onset breast cancer–histopathological and prognostic considerations;Kollias;Br J Cancer,1997

3. The relation between survival and age at diagnosis in breast cancer;Adami;N Engl J Med,1986

4. Younger women with breast carcinoma have a poorer prognosis than older women;Chung;Cancer,1996

5. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age;Winchester;Cancer,1996

Cited by 239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-03

2. Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer;Nanoscale Advances;2024

3. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial;Journal of Clinical Oncology;2023-11-01

4. Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy;World Journal of Clinical Cases;2023-09-26

5. Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare;Geburtshilfe und Frauenheilkunde;2023-05-23